Aphria Earns a New GMP Certification to Aid Its European Expansion
It's about to get a lot easier for medical marijuana patients in Europe to buy their cannabis from Aphria (NYSE: APHA) by the end of the year. One of the company's subsidiaries, Avanti Rx Analytics recently earned a good manufacturing practices (GMP) certification from the Malta Medicines Authority.
Malta might be a small island nation in the Mediterranean, but the certification allows the company to ship products to any European Union member state that permits medical marijuana sales.
Aphria expects to begin making shipments of medical cannabis to CC Pharma GmbH, its German subsidiary, by the end of May. It's hard to say just how much cannabis Aphria will ship to the EU in the quarters ahead, but it's probably safe to assume the Canadian producer won't have trouble meeting demand.
Source Fool.com
